Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8440982 | European Journal of Cancer | 2016 | 8 Pages |
Abstract
No association between prognosis and amount of tumour shrinkage was detected. Interestingly, an increase in tumour size by at least 10% correlated with a worse OS, but re-defining PD as a â¥10% increase in tumour size did not translate into a better discrimination of survival outcomes for responders versus stable disease. Disease control rather than tumour response is a valuable end-point in advanced or metastatic STS receiving palliative anthracycline-based chemotherapy, supporting the use of time-to-event end-points in future STS trials.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Viktor Grünwald, Saskia Litière, Robin Young, Christina Messiou, Michela Lia, Eva Wardelmann, Winette van der Graaf, Alessandro Gronchi, Ian Judson, EORTC STBSG EORTC STBSG,